Start Date

5-27-2021 9:00 AM

End Date

5-27-2021 5:00 PM

Description

  • SGLT2 inhibitors have been shown to have a significant benefit for patients with DM2 or CAD (DAPA-HF, Emperor-reduced)
  • The usage of these medications are low compared to other Goal Directed Medical Therapy.
  • There are multiple contributing factors as to why these medications are underutilized

Our aim is to assess barriers against prescription of SGLT2-i at the time of discharge from TJUH and to increase utilization after placement on formulary.

Keywords

SGLT2 Inhibitors, CAD, DM2, DAPA-HF, Formulary

Comments

Presented at the 2021 House Staff Quality Improvement and Patient Safety Conference

Download

Share

COinS
 
May 27th, 9:00 AM May 27th, 5:00 PM

Improving Utilization of SGLT2 Inhibitors in the Inpatient Setting

  • SGLT2 inhibitors have been shown to have a significant benefit for patients with DM2 or CAD (DAPA-HF, Emperor-reduced)
  • The usage of these medications are low compared to other Goal Directed Medical Therapy.
  • There are multiple contributing factors as to why these medications are underutilized

Our aim is to assess barriers against prescription of SGLT2-i at the time of discharge from TJUH and to increase utilization after placement on formulary.